Yoon, Hyun Ju
Kim, Gi-Cheon
Oh, Sejin
Kim, Hakhyun
Kim, Yong Keon
Lee, Yunji
Kim, Min Seo
Kwon, Gino
Ok, Yeon-Su
Kwon, Ho-Keun
Kim, Hyun Seok http://orcid.org/0000-0003-4498-8690
Funding for this research was provided by:
National Research Foundation of Korea (2020R1A2C3007792, 2017R1A2B2006777, 2021R1A2C2004501)
Korea Health Industry Development Institute (HI14C1324)
Yonsei University | Yonsei University College of Medicine (6-2021-0194)
Article History
Received: 7 April 2022
Revised: 24 July 2022
Accepted: 17 August 2022
First Online: 10 November 2022
Competing interests
: H.S.K. is a founder, chief technology officer, and shareholder of Checkmate Therapeutics Inc. The authors have no other competing or financial conflicts of interest.